Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Sales (2016 - 2025)

Enanta Pharmaceuticals' Return on Sales history spans 14 years, with the latest figure at 0.64% for Q4 2025.

  • For Q4 2025, Return on Sales rose 67.0% year-over-year to 0.64%; the TTM value through Dec 2025 reached 1.07%, up 54.0%, while the annual FY2025 figure was 1.25%, 49.0% up from the prior year.
  • Return on Sales reached 0.64% in Q4 2025 per ENTA's latest filing, up from 1.24% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.64% in Q4 2025 to a low of 3.47% in Q3 2021.
  • Average Return on Sales over 5 years is 1.59%, with a median of 1.5% recorded in 2025.
  • Peak YoY movement for Return on Sales: tumbled -223bps in 2021, then surged 218bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 1.09% in 2021, then dropped by -13bps to 1.23% in 2022, then tumbled by -51bps to 1.86% in 2023, then grew by 29bps to 1.31% in 2024, then soared by 51bps to 0.64% in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Return on Sales are 0.64% (Q4 2025), 1.24% (Q3 2025), and 1.0% (Q2 2025).